Log in

Best Stocks Under $5.00 for 2020

When you think of those mythical, rags-to-riches stories of someone striking it big in the stock market, what you’re most likely thinking of is someone who scored it big with stocks under $5, which are also called penny stocks. Before getting involved in stocks under 5 dollars, there are a few important things to know.

Best Stocks Under $5 - What You Need to Know Before You Buy

Penny stocks don’t literally have to be priced at pennies, though some are just that. Penny stocks refer to stocks that generally trade under $5 a share.

Should I Buy Stocks Under $5?

A broader question might be, “Should I buy stocks?” The answer to both questions is the same: It depends. You should not buy stocks if you don’t have a discriminating sense of how to invest money, or if you don’t have guidance around the topic from someone who does.

With the right knowledge, stocks are an excellent investment, and according to some estimates, far more sound than real estate. Yes, stock prices do fluctuate (sometimes wildly), but over the last several decades, they have outperformed real estate in some regards.

Investors who know what they’re doing with stocks can make huge gains, build enormous wealth, and create exponential financial success. Stocks under $5, in particular, present an incredible opportunity to make huge gains.

It all comes down to research.

You never want to sink all of your investment cash into just one basket. Estimates vary on the exact percentage, but most experts agree that the majority of your portfolio should be invested in solid, stable companies. That said, stocks under $5 can be a good place to do a little value investing and give some growth to your cash.

It’s important to keep in mind that there are many trading strategies in relation to the stock market, and investing in undervalued, up-and-coming companies is only one strategy. For example, some investors prefer to focus on stocks that pay out dividends, where each share pays out dividend payments of company profit—and a large number of shares creates a solid cash flow. Other investors like to buy shares in specific industries, like tech stocks, or they may choose to ride the market as they engage in the ups and downs of day trading, flipping stocks for profit.

Whichever stock trading strategy you prefer, penny stocks can be some of the best growth stocks for their undervalued cost—if you trade the right way.

What Are Penny Stocks?

Stocks that trade under $5 per share are also called penny stocks. There are many cheap stocks to buy which can be had for under $5 per share, including dollar stocks, penny stocks, and stocks that sell for fractions of a penny.

While many penny stocks belong to startup companies in potentially risky market sectors, there are also plenty of established businesses trading on normal markets at under $5 per share. These publicly traded securities can certainly be viewed as a less risky proposition, due to their established company history. And if they trade on a regulated market, they have to make their accounting transparent, which eliminates a lot of investor risk.

But by-and-large, penny stocks are usually associated with smaller companies that are newer or undervalued, and not yet recognized by the market. There tend to be fewer shares of these stocks available, meaning wider spreads between bids and asking prices. The companies themselves tend to be considered speculative investments. All of this carries a certain element of risk.

That said, investing in these small cap companies can provide an opportunity to make huge gains. To someone who doesn’t know what they’re doing, penny stocks can be a total gamble. To someone who does know what they’re doing, penny stocks can provide some lucrative revenue growth.

What Are the Rewards of Stocks Under $5?

As mentioned, penny stocks present huge opportunities for growth. Take True Religion as an example—an apparel company based in Vancouver, Canada. This designer-jeans outfit was trading for $0.67 per share in July of 2004. Just nine years later, TowerBrook Capital Partners acquired the company and paid $32 for every share...a whopping 4676% profit.

Can you think of any “normal stocks” that offered investors the same gains? They’re few and far between (though they do exist). These are the types of profit margins that traders dream of earning.

Another advantage of penny stocks is that they can be an easy way for small-time investors to enter the market. You don’t necessarily have to sink everything into some sort of risky biotech company. There are plenty of brand-name companies that are trading at under $5. Purchasing shares of these recognized businesses could be your chance to enter the stock market in an affordable way—and cash out big if things work out.

It’s not just about price, but about volume: A $500 investment might only buy you 5-10 shares of a recognizable blue-chip stock or it could buy you 100+ shares of a stock priced at $5 and below. If that company grows and becomes a mid-cap stock, you’ll see a lot more profit than you would have by investing in a more “normal” stock.

For that very same reason, penny stocks may allow you to diversify your holdings to a greater extent, with less money (if you want to eschew mutual funds and pick stocks yourself). With just $100 in the market, you could buy ten shares of stock in ten different industries.

Some penny stocks are shares of companies outside the US. This can be your opportunity to dabble in international business and obtain some revenue from the global market—without having to worry about tariffs and exchange rates. Of course, in this case, you cannot just be a savvy investor; you have to be well abreast of the news and current events.

What Are the Risks of Stocks Under $5?

Many stocks under $5 are companies that may be startups or riskier business ventures. One of the biggest examples is biotech, an industry with larger startup costs and huge risks for investors. A startup company may discover the cure for cancer, in which case, you can cash out as a billionaire. Or, they may not, and they’ll take all your money with them when they fold.

Another disadvantage to stocks under $5 is that they may be stocks of a company that’s about to go bankrupt. They could be desperately selling shares of stock to raise money, or to help their executives bail out with a parachute built from your investment. Newly formed startups may also be on the verge of bankruptcy, and because of their lack of established history, no one may even know.

Occasionally penny stocks will be part of a “pump and dump” scam, where investors build excitement over a particular stock to drive up the price. They may “leak” information that a startup energy company struck crude oil gold or put forth an imaginative but enticing earnings estimate for the next quarter. As the stock value wildly climbs out of control (far beyond the actual value of the market cap), hoodwinked investors pour their dollars into the company. Then it crashes, and the only ones who benefit are the scammers who bought into the stock before they made it popular.

Another more prosaic risk of stocks under $5 is that they may just not go anywhere, hovering under $5 for years on end. While this is certainly better than losing all your money, it’s not so conducive to portfolio growth.

Yet another disadvantage to stocks under $5 is their low trading volume. They can be harder to unload if you need to, because you may not find a willing buyer. Moreover, many penny stocks of younger upstart companies will most likely not pay out dividends. You are only purchasing the stock to leverage a change in its price—or hoping that in the future they will play into your dividend investing strategy.

As you can see, there are some risks and volatility associated with stocks under $5. However, it once again all comes down to playing it smart and doing your research. There are plenty of resources which will tell you about the most volatile stocks, along with providing stats to gauge their future possibilities.

If you have a good head for what’s going on, you won’t fall for scams or pour all your money into a pipe dream. The best traders know which stocks to watch; they understand the ins and outs of dividend yield and market capitalization—and can leverage these stats into higher amounts of revenue. There’s no secret to what they’re doing. They’re actively learning and keeping their eyes on the best times to buy stocks at 52 week low points. They know when to hold their assets, and when to sell them.

How to Trade Stocks Under $5?

Some stocks under $5 are traded on the New York Stock Exchange and NASDAQ. However, most stocks under $5 trade through over the counter transactions (OTC). Everything about these OTC transactions is done electronically through the OTC Bulletin Board (OTCBB). Companies that are traded on the OTCBB must still meet requirements from the SEC and FINRA. However, these companies don’t meet the requirements for trading on a larger market.

There are still more stocks under $5 that don’t even meet the requirements to be traded on the OTCBB. These stocks can be found on a listing service called Pink Sheets (so named because the stocks were once listed on pink sheets of paper). These companies are too small to be listed on a national exchange, or may not wish to make their accounting statements public—which means they don’t have to file with the SEC, and can’t be listed on a publicly-traded market.

As you might expect, these Pink Sheet stocks can carry significant risks. They can be difficult to analyze because of the lack of transparency around their business; investors should use caution and due diligence when purchasing them.

What Are the Best Stocks Under $5?

Now that we’ve reviewed the pros and cons of stocks under $5 and explained how they work, let’s address the question that every investor wants to know: how do I actualize this information?

It can be hard to find good stocks under $5, even though the stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs, and the price-to-earnings ratios of most S&P 500 companies make purchasing shares look like an expensive proposition. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive, both in terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $5.00 per share.

Stocks Under 5 Dollars

Value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $5.00 requires investors to look at smaller and riskier companies in sectors that are either undiscovered or unrecognized by the market as a whole. When looking at cheap stocks to buy, some of them may not look especially attractive today, but long-term investors will recognize profit if they are willing to exercise patience and hold onto shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are small. As a result, they’re considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unrecognized or untested areas of the market. You may find even find crypto stocks, marijuana stocks, and bitcoin stocks on this list. Others have been beaten up by Mr. Market after a long period of slowing profits but are now actively trying to turn around their business and bounce back.

This low-priced list of stocks showcases a lot of different industries, but these picks all carry two common characteristics: They all have a super-low share price of $5.00 or less, and they all consistently receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Selecta Biosciences logo

#1 - Selecta Biosciences

NASDAQ:SELB
Stock Price: $3.92 (+$0.03)
PE Ratio: -3.50
Market Cap: $342.96 million
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.80 (73.5% Upside)
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc.; and a strategic partnership with Asklepios BioPharmaceutical, Inc. for the development, manufacture, and commercialization of targeted therapeutics for adeno-associated virus gene therapies in the areas of high medical need. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Baudax Bio logo

#2 - Baudax Bio

NASDAQ:BXRX
Stock Price: $4.03 (+$0.05)
PE Ratio: -1.16
Market Cap: $70.80 million
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.00 (222.6% Upside)
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Identiv logo

#3 - Identiv

NASDAQ:INVE
Stock Price: $4.12 (-$0.31)
PE Ratio: -21.68
Market Cap: $72.09 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.50 (106.3% Upside)
Identiv, Inc. operates as a security technology company that secures data, physical places, and things worldwide. It operates through two segment, Premises and Identity. The Premises segment offers modular Hirsch MX controllers that allow customers to start with a small system and expand over time; Hirsch Velocity software platform for centralized management of access and security operations across an organization; federal identity, credential and access management architecture, an access control system; TouchSecure door readers that provide various features to support security standards; and global services to support system design, deployment, and managed services across customers premises security lifecycle. The Identity segment provides smart card readers, which include various contact, contactless, portable, and mobile smart card readers, as well as tokens and terminals to enable logical access, and security and identification applications, such as national ID, payment, e-health, and e-government. The company also offers near field communication and radio frequency identification products, including inlays and inlay-based; labels and tags, as well as other radio frequency and integrated circuits components for use in various applications, such as virtual reality, games, loyalty cards, mobile payment systems, transit and event ticketing, and brand authenticity foe pharmaceuticals, consumer goods, hospital resource management, cold-chain management, and others; and access cards. It markets and sells its products through original equipment manufacturers, dealers, systems integrators, value added resellers, resellers, and Internet, as well as directly to end users. The company was formerly known as Identive Group, Inc. and changed its name to Identiv, Inc. in May 2014. Identiv, Inc. was founded in 1990 and is headquartered in Fremont, California.
Strongbridge Biopharma logo

#4 - Strongbridge Biopharma

NASDAQ:SBBP
Stock Price: $3.70 (+$0.17)
PE Ratio: -3.63
Market Cap: $200.72 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.88 (166.9% Upside)
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Sientra logo

#5 - Sientra

NASDAQ:SIEN
Stock Price: $3.73 (-$0.03)
PE Ratio: -1.42
Market Cap: $186.36 million
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.05 (89.3% Upside)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Fortress Biotech logo

#6 - Fortress Biotech

NASDAQ:FBIO
Stock Price: $2.83 (+$0.18)
PE Ratio: -3.08
Market Cap: $233.40 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.20 (225.1% Upside)
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
Livexlive Media logo

#7 - Livexlive Media

NASDAQ:LIVX
Stock Price: $3.28 (-$0.05)
PE Ratio: -4.43
Market Cap: $193.13 million
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.21 (59.0% Upside)
LiveXLive Media, Inc., a digital media company, engages in the acquisition, distribution, and monetization of live music, Internet radio, and music-related streaming and video content. The company operates LiveXLive, a live music streaming platform; and Slacker Radio, a streaming music service, as well as produces original music-related content. It also produces, edits, curates, and streams live music events through broadband transmission over the Internet and satellite networks to its users; provides digital Internet radio and music services to users online and through original equipment manufacturers on a white label basis; and offers ancillary products and services, such as regulatory and post-implementation support services. In addition, the company offers an application that provides access to live events, audio streams, original episodic content, podcasts, video on demand, real-time livestreams, and social sharing of content. The company was formerly known as Loton, Corp. and changed its name to LiveXLive Media, Inc. in August 2017. LiveXLive Media, Inc. was founded in 2009 and is headquartered in West Hollywood, California.
Entasis Therapeutics logo

#8 - Entasis Therapeutics

NASDAQ:ETTX
Stock Price: $2.40
PE Ratio: -0.69
Market Cap: $35.07 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.50 (295.8% Upside)
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.
SCYNEXIS logo

#9 - SCYNEXIS

NASDAQ:SCYX
Stock Price: $0.79
PE Ratio: -1.34
Market Cap: $77.86 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.60 (483.8% Upside)
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Vascular Biogenics logo

#10 - Vascular Biogenics

NASDAQ:VBLT
Stock Price: $1.14 (-$0.05)
PE Ratio: -1.97
Market Cap: $47.80 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.50 (207.0% Upside)
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase III clinical trials for recurrent platinum-resistant ovarian cancer, as well as for Phase II clinical trials for iodine-resistant differentiated thyroid cancer. The company is also developing VB-111, which is in Phase I clinical trials for the treatment of patients with various types of advanced metastatic cancer types, including thyroid cancer, neuroendocrine cancer, renal cell carcinoma, and lung cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; VB-201, a Lecinoxoid-based compound for the control of chronic inflammatory disorders; and VB-600 that is in pre-clinical stage for targeting of MOSPD2 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
Proteostasis Therapeutics logo

#11 - Proteostasis Therapeutics

NASDAQ:PTI
Stock Price: $1.63 (-$0.04)
PE Ratio: -1.54
Market Cap: $85 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.75 (252.8% Upside)
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Geron logo

#12 - Geron

NASDAQ:GERN
Stock Price: $1.84 (-$0.12)
PE Ratio: -5.11
Market Cap: $368.67 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.50 (90.2% Upside)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
PhaseBio Pharmaceuticals logo

#13 - PhaseBio Pharmaceuticals

NASDAQ:PHAS
Stock Price: $4.44 (+$0.16)
PE Ratio: -2.71
Market Cap: $127.79 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.00 (147.7% Upside)
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. The company has an agreement with Viamet Pharmaceuticals Holdings, LLC and Selenity Pharmaceuticals (Bermuda) Ltd. to develop PB6440, a lead development compound for treatment of resistant hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.
Paratek Pharmaceuticals logo

#14 - Paratek Pharmaceuticals

NASDAQ:PRTK
Stock Price: $4.57 (+$0.18)
PE Ratio: -1.31
Market Cap: $197.11 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $18.50 (304.8% Upside)
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
OptiNose logo

#15 - OptiNose

NASDAQ:OPTN
Stock Price: $4.59 (+$0.24)
PE Ratio: -1.79
Market Cap: $210.71 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $22.20 (383.7% Upside)
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Applied Genetic Technologies logo

#16 - Applied Genetic Technologies

NASDAQ:AGTC
Stock Price: $4.60 (+$0.12)
PE Ratio: -2.10
Market Cap: $118.52 million
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.50 (258.7% Upside)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. The company also has initiated one preclinical program in otology and three preclinical programs in targeting central nervous system disorders, including one in adrenoleukodystrophy. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited and University of Florida; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida.
BioDelivery Sciences International logo

#17 - BioDelivery Sciences International

NASDAQ:BDSI
Stock Price: $4.94 (+$0.31)
PE Ratio: -54.83
Market Cap: $493.03 million
Consensus Rating: Buy (7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.71 (76.5% Upside)
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Mechel PAO logo

#18 - Mechel PAO

NYSE:MTL
Stock Price: $1.80 (-$0.01)
Market Cap: $374.64 million
Consensus Rating: Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.30 (583.3% Upside)
Mechel PAO, together with its subsidiaries, engages in mining, steel, and power businesses in Russia, Asia, Europe, the Commonwealth of Independent States, the Middle East, the United States, and internationally. Its Mining segment produces and sells coking, metallurgical, and steam coal; coke; chemical products, including coal tar, coal benzene, and other compounds; and iron ore and iron ore concentrates. The company's Steel segment produces and sells semi-finished steel products, long steel products, and carbon and stainless flat products; ferrosilicon products; and pig iron, as well as metal products, including wire products, stampings and forgings, structural shapes, beams, and rails. Its Power segment generates and supplies electricity, heat energy, and other power resources to third parties. Mechel PAO also offers sea, rail, and motor transportation logistics services to third parties. The company was formerly known as Mechel OAO and changed its name to Mechel PAO in March 2016. Mechel PAO was founded in 2003 and is based in Moscow, Russia.
ASE Technology logo

#19 - ASE Technology

NYSE:ASX
Stock Price: $4.06 (-$0.09)
PE Ratio: 14.00
Market Cap: $8.79 billion
P/E Ratio: 14.0
Dividend Yield: 2.61 %
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
ASE Technology Holding Co., Ltd. provides a range of semiconductors packaging and testing, and electronic manufacturing services (EMS) in the United States, Taiwan, Asia, Europe, and internationally. The company offers packaging services, including flip-chip ball grid array (BGA), flip-chip chip scale package (fcCSP), advanced chip scale packages (aCSP), quad flat packages, thin quad flat packages, bump chip carrier and quad flat no-lead (QFN) packages, advanced QFN packages, plastic BGAs, and 3D chip packages; stacked die solutions in various package types; and copper and silver wire bonding solutions, as well as module-based solutions. It also provides advanced packages, such as flip-chip BGA; heat-spreader FCBGA; flip-chip CSP; hybrid FCCSP; flip-chip package in package and package on package (POP); advanced single sided substrate; high-bandwidth POP; fan-out wafer level packaging; SESUB; and substrate interposer packages. In addition, the company offers IC wire bonding packages; system-in-package products (SiP) and modules; and interconnect materials, as well as assembles automotive electronic products. Further, it provides a range of semiconductor testing services, including front-end engineering testing, wafer probing, logic/mixed-signal/RF module and SiP/MEMS/discrete final testing, and other test-related services, as well as drop shipment services. Additionally, the company offers develops, constructs, sells, leases, and manages real estate properties; produces substrates; offers information software, equipment leasing, financing, investment advisory, and warehousing management services; and manufactures computer assistance systems and related peripherals, electronic components, communication peripherals, telecommunications equipment, and motherboards. The company serves customers in communication, computing, and consumer electronics/industrial/automotive sectors. ASE Technology Holding Co., Ltd. was founded in 1984 and is based in Kaohsiung, Taiwan.
Kadmon logo

#20 - Kadmon

NYSE:KDMN
Stock Price: $4.66 (+$0.11)
PE Ratio: -6.66
Market Cap: $745.72 million
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.00 (157.5% Upside)
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.